samedan logo
 
 
 
spacer
home > ebr > autumn 2009 > nanotechnology: past, present and future
PUBLICATIONS
European Biopharmaceutical Review

Nanotechnology: Past, Present and Future

 

Over the past 30 years, nanotechnology has shown great promise in advancing the fields of medicine, cosmetics, electronics, material sciences, information technology, energy production and engineering. During this time, public and private funding in the area of nanotechnology has increased to advance the science and commercialisation of nanotechnology-based products. For example, the US National Nanotechnology Initiative’s (NNI) 2010 budget is expected to reach $1.64 billion to support basic research, infrastructure development and technology transfer in the fields of healthcare, electronics, aeronautics, agriculture, food and energy. From this proposed budget, $326 million has been allocated to the National Institutes of Health (NIH) to conduct nanotechnologyrelated medical research (1). According to the Woodrow Wilson International Center for Scholars Project on Emerging Nanotechnologies (PEN), over 800 nanotechnology-based consumer products are currently on the market, with a total value of $147 billion (2). The analysis firm Lux Research predicts that nanotechnology products will reach a total value of $3.1 trillion by 2015. Similar trends are also predicted for nanotechnology-based drug products, whose total market value may reach $200 billion by 2015 (3). It is expected that nanotechnology-based products will continue to be developed as novel and effective therapies move from the bench to the clinic.

NANOTECHNOLOGY: TODAY

The concept of nanotechnology in targeted therapy was first introduced by Paul Ehrlich, the 1908 Nobel Laureate. Ehrlich conceived the notion of ‘magic bullets’: specific compounds that seek out the disease causing organism and destroy it without harming other parts of the body. This is the promise that today’s nanotechnology drug products offer for diagnosing, imaging and treating diseases. The US NNI defines nanotechnology as: “The understanding and control of matter at dimensions between approximately one and 100 nanometers where unique phenomena enable novel applications” (4).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Dr Nakissa Sadrieh obtained her doctorate in Toxicology in 1993 from Rutgers University in New Jersey. Following a postdoctoral fellowship in the Laboratory of Chemical Carcinogenesis at the National Cancer Institute, Nakissa joined the Food and Drug Administration (FDA) in 1996. She is currently the Associate Director for Research Policy and Implementation in the Office of Pharmaceutical Science within the Center for Drug Evaluation and Research (CDER). Her work is aimed at filling research needs to help address regulatory questions. 

Dr Banu Zolnik is a pharmacologist in the Science and Research Staff of the Office of Pharmaceutical Science within CDER, FDA. Prior to joining the FDA in 2008, Banu worked as a postdoctoral fellow in the Nanotechnology Characterization Laboratory at the National Cancer Institute. Banu obtained her doctorate in Pharmaceutical Sciences from the University of Connecticut in 2005. She received her Bachelor of Science in Pharmacy from Istanbul University in Turkey in 1997. Her research interests are related to regulatory aspects of the development of novel dosage drug delivery systems, such as nanoparticles, microspheres, emulsions and liposomes.

spacer
Nakissa Sadrieh
spacer
spacer
spacer
Banu Zolnik
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Team Consulting expands facilities to meet client demand

To meet growing client demand, Team Consulting, a medical device design and development consultancy based in Ickleton, Cambridge, has expanded its facilities to now offer over 5,500 sq ft of lab spaces. Based in the picturesque 13th century Abbey Barns site, the company’s expansion sees the addition of a whole new building with several high-spec lab spaces, design facilities and collaborative workspaces.
More info >>

White Papers

BioT ULT Transporter

BioCision

The growth of biobanking, cell therapy, and complex biopharmaceutical therapies like cancer vaccines has created a strong need for products and processes to ensure the stability of temperature­-sensitive biospecimens. Proper collection, handling, characterization, packaging and shipping of these materials is critical, as poor sample handling impacts researchers working on discovery with patient samples, as well as clinicians treating patients with cutting edge therapies. This white paper describes in detail the BioCision BioT™ ULT Transporter, the first-of-its-kind dry ice-based portable cooling system that maintains a stable -75° to -50°C environment for over 24 hours on one charge of dry ice, enabling reliable handling and transfer of valuable temperature-sensitive biospecimens as part of a larger cold chain standardization process.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement